Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6450MR)

This product GTTS-WQ6450MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6450MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6847MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ9282MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ8023MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ5303MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ6487MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ10479MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ12689MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ3019MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW